期刊文献+

5-氨基水杨酸结肠定位缓释微丸质量控制方法研究

下载PDF
导出
摘要 目的:建立5-氨基水杨酸(5-ASA)结肠定位缓释胶囊的质量控制方法。方法:采用高效液相色谱法测定5-ASA结肠定位缓释胶囊的含量,以C18柱作为色谱柱,甲醇-缓冲液(25∶75)为流动相,检测波长为254 nm,按外标法定量。结果:该方法线性范围为20~120μg/mL,r=0.999 8(n=3)。5-氨基水杨酸口服结肠定位释药缓释胶囊的平均含量为102.45%(n=3),RSD=0.56%。平均加样回收率为100.05%(n=9),RSD=0.50%。结论:高效液相色谱法专属性好,结果准确,可用于含量测定并可有效地控制该药的质量。
出处 《天津医科大学学报》 2011年第1期111-112,116,共3页 Journal of Tianjin Medical University
  • 相关文献

参考文献6

二级参考文献32

  • 1Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid [ J ]. J Clin Gastroenterol, 1990, 12 (2) : 198-199.
  • 2uluvath PJ, Ninkovic M, Calam J, et al. Mesalazine induced interstitial nephritis [J]. Gut, 1994, 35 (10) :1493-1496.
  • 3Sviri S, Gafanovich I, Kramer MR, et al. Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature EJ]. J Clin Gastroenterol,1997,24(1):34-36.
  • 4Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease[J]. Aliment-Pharmacol-Ther, 2000,14(1) : 1-6.
  • 5Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine [J]. Gastroenterology, 1995, 108 (5) :1427-1433.
  • 6Azad Khan AK, Nurazzaman M, Truelove SC. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man [J]. J Med Genet, 1983,20 (1) :30-36.
  • 7Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis : results of a controlled trial[J]. Am J Gastroenterol, 1993,88(8) : 1188-1197.
  • 8Axelsson LG, Landstrom E, Bylund-Fellenius AC,et al. Experimental colitis induced by dextran sulphate sodium in mice : beneficial effects of sulphasalazine and olsalazine[J]. Aliment Pharmacol Ther, 1998,12 (9) :925-934.
  • 9Kruis W, Brandes JW, Schreiber S,et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis [J]. Aliment Pharmacol Ther,1999,13(9):1253.
  • 10Kimura I, Kumamoto T, Matsuda A, et al. Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine[J]. Arzneimittel forschung, 1998,48(10) : 1007-1011.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部